

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|----------------|----------------------|-------------------------|------------------|
| 09/700,625 | 02/01/2001 | Jana Sawynok | DALHO1290-1 | 7582 |
| 75 | 590 04/23/2003 | | | |
| STEPHEN E. REITER FOLEY& LARDNER P. O. BOX 80278 | | | EXAMINER | |
| | | | WARE, TODD | |
| SAN DIEGO, CA | LA 92138 | | ART UNIT | PAPER NUMBER |
| | | | 1615 | <u> </u> |
| | | | DATE MAILED: 04/23/2003 | 22 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| Application No. Applicant(s) | | | | | |
|---|--|--|--|--|--|
| 09/700,625 SAWYNOK ET AL. | | | | | |
| Office Action Summary Examiner Art Unit | | | | | |
| Todd D Ware 1615 | | | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status | | | | | |
| 1) Responsive to communication(s) filed on <u>28 January 2003</u> . | | | | | |
| 2a)⊠ This action is FINAL . 2b)□ This action is non-final. | | | | | |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | |
| Disposition of Claims | | | | | |
| 4) Claim(s) 26,37-44,49-53 and 72-83 is/are pending in the application. | | | | | |
| 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | |
| 5) Claim(s) is/are allowed. | | | | | |
| 6)⊠ Claim(s) <u>26,37-44,49-53 and 72-83</u> is/are rejected. | | | | | |
| 7) Claim(s) is/are objected to. | | | | | |
| 8) Claim(s) are subject to restriction and/or election requirement. Application Papers | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | |
| 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. | | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | |
| 12) The oath or declaration is objected to by the Examiner. | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | |
| a)⊠ All b)☐ Some * c)☐ None of: | | | | | |
| 1. Certified copies of the priority documents have been received. | | | | | |
| 2. Certified copies of the priority documents have been received in Application No | | | | | |
| 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). | | | | | |
| a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. | | | | | |
| Attachment(s) | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) | | | | | |

Application/Control Number: 09/700,625

Art Unit: 1615

DETAILED ACTION

Receipt of amendment filed 1-28-03 is acknowledged. Claims 26 and 37 have been amended and new claims 74-83 have been added as requested. Claims 26, 37-44, 49-53, and 72-83 are pending.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 26, 37-43, 49-51, 72-74, 76, 79, and 81 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Amer (5,266,571; hereafter '571).
- 3. '571 discloses topical compositions for treating hemorrhoids comprising nefazodone. The concentration of active overlaps with the instant claimed range, is administered in a cream, gel, or ointment and includes a neutralizing agent and/or carrier in the formulation (abstract; C 2, L 52-54, C 3, L 45-64, C 5, L 10-C6, L 18; claims).

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Application/Control Number: 09/700,625

Art Unit: 1615

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

- 5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 6. Claims 44, 52-53, 75, 77-78, 80, and 82-83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Amer (5,266,571; hereafter '571) in view of Knepp et al (1990).
- 7. '571 teaches topical compositions for treating hemorrhoids comprising nefazodone. The concentration of active overlaps with the instant claimed range, is administered in a cream, gel, or ointment and includes a neutralizing agent and/or carrier in the formulation (abstract; C 2, L 52-54, C 3, L 45-64, C 5, L 10-C6, L 18; claims). '571 does not teach inclusion of a penetration enhancing agent or a slow release delivery vehicle such as a liposome, microsphere or polymer stabilized crystal in the formulation.
- 8. Knepp teaches topical delivery of an active agent in a liposome combined with a penetration enhancing agent to provide controlled release of the active agent.

10

Page 4

Application/Control Number: 09/700,625

Art Unit: 1615

9. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to combine '571 and Knepp with the motivation of controlling the release of nefazodone in the treatment of hemorrhoids.

Response to Arguments

10. Applicant's arguments with respect to claims 26, 37-44, 49-53, and 72-83 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Page 5

Application/Control Number: 09/700,625

Art Unit: 1615

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

tw April 18, 2003 THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600